U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Renal cell carcinoma

MedGen UID:
766
Concept ID:
C0007134
Neoplastic Process
Synonyms: Adenocarcinoma Of Kidney; Adenocarcinoma Of Kidneys; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell; Cancer, Renal Cell; Carcinoma, Nephroid; Carcinoma, Renal; Carcinoma, Renal Cell; Carcinomas, Renal Cell; Kidney, Adenocarcinoma Of; Nephroid Carcinoma; Nephroid Carcinomas; Renal Adenocarcinoma; Renal Adenocarcinomas; Renal Carcinoma; Renal Carcinomas; Renal Cell Adenocarcinoma; Renal Cell Adenocarcinomas; Renal Cell Cancer; Renal Cell Cancers; Renal Cell Carcinoma; Renal Cell Carcinomas
SNOMED CT: Renal cell carcinoma - morphology (41607009); Renal cell carcinoma (702391001); Hypernephroma (702391001); Renal cell carcinoma (41607009); Renal cell adenocarcinoma (41607009)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
Concept ID:
CN307044
Finding
Source: Orphanet
clinical entity without genetic inheritance.
 
HPO: HP:0005584
Monarch Initiative: MONDO:0005086
OMIM®: 144700
Orphanet: ORPHA217071

Definition

A type of carcinoma of the kidney with origin in the epithelium of the proximal convoluted renal tubule. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRenal cell carcinoma
Follow this link to review classifications for Renal cell carcinoma in Orphanet.

Conditions with this feature

Von Hippel-Lindau syndrome
MedGen UID:
42458
Concept ID:
C0019562
Disease or Syndrome
Von Hippel-Lindau syndrome (VHL) is characterized by hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma and paraganglioma; pancreatic cysts and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cystadenomas. Retinal hemangioblastomas may be the initial manifestation of VHL and can cause vision loss. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.
Colorectal cancer
MedGen UID:
83428
Concept ID:
C0346629
Neoplastic Process
Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.
Hereditary leiomyomatosis and renal cell cancer
MedGen UID:
353771
Concept ID:
C1708350
Neoplastic Process
FH tumor predisposition syndrome is characterized by cutaneous leiomyomata, uterine leiomyomata (fibroids), and/or renal tumors. Pheochromocytoma and paraganglioma have also been described in a small number of families. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 30 years, increasing in size and number with age. Uterine leiomyomata tend to be numerous and large; age at diagnosis ranges from 18 to 53 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors are usually unilateral, solitary, and aggressive. They are associated with poor survival due to clinical aggressiveness and propensity to metastasize despite small primary tumor size. The median age of detection is approximately age 40 years.
Tuberous sclerosis 1
MedGen UID:
344288
Concept ID:
C1854465
Disease or Syndrome
Tuberous sclerosis complex (TSC) involves abnormalities of the skin (hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques, ungual fibromas); brain (subependymal nodules, cortical tubers, and subependymal giant cell astrocytomas [SEGAs], seizures, TSC-associated neuropsychiatric disorder [TAND]); kidneys (benign renal angiomyolipomas, epithelial cysts, oncocytoma, renal cell carcinoma); heart (rhabdomyomas, arrhythmias); and lungs (lymphangioleiomyomatosis [LAM], multifocal micronodular pneumonocyte hyperplasia). Central nervous system-related problems (including TAND) are the leading cause of morbidity, whereas kidney disease is the leading cause of mortality.
Tuberous sclerosis 2
MedGen UID:
348170
Concept ID:
C1860707
Disease or Syndrome
Tuberous sclerosis complex (TSC) involves abnormalities of the skin (hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques, ungual fibromas); brain (subependymal nodules, cortical tubers, and subependymal giant cell astrocytomas [SEGAs], seizures, TSC-associated neuropsychiatric disorder [TAND]); kidneys (benign renal angiomyolipomas, epithelial cysts, oncocytoma, renal cell carcinoma); heart (rhabdomyomas, arrhythmias); and lungs (lymphangioleiomyomatosis [LAM], multifocal micronodular pneumonocyte hyperplasia). Central nervous system-related problems (including TAND) are the leading cause of morbidity, whereas kidney disease is the leading cause of mortality.
Paragangliomas 4
MedGen UID:
349380
Concept ID:
C1861848
Disease or Syndrome
Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck paragangliomas [HNPGLs]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, extra-adrenal sympathetic paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCCs result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas. Additional tumors reported in individuals with hereditary PGL/PCC syndromes include gastrointestinal stromal tumors (GISTs), pulmonary chondromas, and clear cell renal cell carcinoma.
NONPAPILLARY RENAL CARCINOMA 1 LOCUS
MedGen UID:
413407
Concept ID:
C2750825
Finding
Renal cell carcinoma, Xp11-associated
MedGen UID:
477077
Concept ID:
C3275446
Neoplastic Process
Xp11 translocation renal cell carcinomas (RCCX1) are a group of neoplasms distinguished by chromosomal translocations with breakpoints involving the TFE3 gene within tumor cells. The result is a TFE3 transcription factor gene fusion with 1 of multiple reported genes including ASPRCR1 (606236) on chromosome 17q25 and PRCC (179755) on 1q21, and more rarely, NONO (300084) on Xq13, SFPQ (605199) on 1p34, CLTC (118955) on 17q23, and unknown genes on chromosomes 3 and 10. Xp11 translocations are often found in pediatric tumors and less commonly in adults. However, adult cases may outnumber pediatric cases since renal cell carcinoma is more common in the adult population. Prior chemotherapy is a known risk factor for Xp11 translocations. Histology shows both clear cells and papillary architecture, often with abundant psammoma bodies, although variable histologic features have been observed (review by Ross and Argani, 2010). For a discussion of genetic heterogeneity of renal cell carcinoma, see RCC (144700).
BAP1-related tumor predisposition syndrome
MedGen UID:
482122
Concept ID:
C3280492
Disease or Syndrome
BAP1 tumor predisposition syndrome (BAP1-TPDS) is associated with an increased risk for a specific skin lesion, BAP1-inactivated melanocytic tumors (BIMT; formerly called atypical Spitz tumors), and the following cancers, in descending order of frequency: uveal (eye) melanoma (UM), malignant mesothelioma (MMe), cutaneous melanoma (CM), renal cell carcinoma (RCC), basal cell carcinoma (BCC), meningioma, and cholangiocarcinoma. Onychopapillomas, hepatocellular carcinoma, and ovarian sex cord-stromal tumors may also be associated with BAP1-TPDS. Affected individuals can have more than one type of primary cancer. In general, the median age of onset of these tumors is younger than in the general population. UM tends to be a more aggressive class 2 tumor with higher risk for metastasis and reduced survival compared to UM occurring in the general population. RCC is usually of clear cell morphology, but other pathologies have been reported. MMe, especially pleural, has better survival and responds better to platinum chemotherapy than MMe not associated with a germline BAP1 pathogenic variant. The penetrance, natural history, life-time cancer risk for carriers, and frequencies of BAP1-associated tumors are yet to be fully determined.
Birt-Hogg-Dube syndrome 1
MedGen UID:
1051978
Concept ID:
CN375946
Disease or Syndrome
The clinical characteristics of Birt-Hogg-Dubé syndrome (BHDS) include cutaneous manifestations (fibrofolliculomas, acrochordons, angiofibromas, oral papules, cutaneous collagenomas, and epidermal cysts), pulmonary cysts / history of pneumothorax, renal cysts, and various types of renal tumors. Disease severity can vary significantly even within the same family. Skin lesions typically appear between the second and fourth decades of life and typically increase in size and number with age. Lung cysts are mainly in the basal lung regions; most individuals are asymptomatic but at high risk for spontaneous pneumothorax. Renal tumors can be bilateral and multifocal. The most common renal tumors are a hybrid of oncocytoma and chromophobe histologic cell types (oncocytic hybrid tumor); clear cell carcinoma and oncocytoma are also common.

Professional guidelines

PubMed

Powles T, Albiges L, Bex A, Comperat E, Grünwald V, Kanesvaran R, Kitamura H, McKay R, Porta C, Procopio G, Schmidinger M, Suarez C, Teoh J, de Velasco G, Young M, Gillessen S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Ann Oncol 2024 Aug;35(8):692-706. Epub 2024 May 22 doi: 10.1016/j.annonc.2024.05.537. PMID: 38788900
Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR
Curr Treat Options Oncol 2023 Dec;24(12):1889-1916. Epub 2023 Dec 28 doi: 10.1007/s11864-023-01161-5. PMID: 38153686Free PMC Article
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L
G Ital Nefrol 2022 Jun 20;39(3) PMID: 35819037

Recent clinical studies

Etiology

Lemelin A, Takemura K, Heng DYC, Ernst MS
Hematol Oncol Clin North Am 2023 Oct;37(5):925-935. Epub 2023 Jun 1 doi: 10.1016/j.hoc.2023.04.016. PMID: 37270385
Msaouel P, Genovese G, Tannir NM
Hematol Oncol Clin North Am 2023 Oct;37(5):977-992. Epub 2023 May 25 doi: 10.1016/j.hoc.2023.04.019. PMID: 37244822Free PMC Article
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L
G Ital Nefrol 2022 Jun 20;39(3) PMID: 35819037
Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L
Crit Rev Oncol Hematol 2021 Apr;160:103287. Epub 2021 Mar 19 doi: 10.1016/j.critrevonc.2021.103287. PMID: 33753250
Ray S, Jones R, Pritchard-Jones K, Dzhuma K, van den Heuvel-Eibrink M, Tytgat G, van der Beek J, Oades G, Murphy D
Pediatr Blood Cancer 2020 Nov;67(11):e28675. Epub 2020 Sep 1 doi: 10.1002/pbc.28675. PMID: 32869954

Diagnosis

Msaouel P, Genovese G, Tannir NM
Hematol Oncol Clin North Am 2023 Oct;37(5):977-992. Epub 2023 May 25 doi: 10.1016/j.hoc.2023.04.019. PMID: 37244822Free PMC Article
Mendhiratta N, Muraki P, Sisk AE Jr, Shuch B
Urol Oncol 2021 Jun;39(6):327-337. Epub 2021 May 24 doi: 10.1016/j.urolonc.2021.04.013. PMID: 34034966
Pivovarčíková K, Michalová K, Hes O
Cesk Patol 2020 Summer;56(3):130-139. PMID: 33076665
Honda Y, Nakamura Y, Goto K, Terada H, Sentani K, Yasui W, Sekino Y, Hayashi T, Teishima J, Matsubara A, Akagi M, Fuji T, Baba Y, Iida M, Awai K
Abdom Radiol (NY) 2018 Jul;43(7):1540-1545. doi: 10.1007/s00261-018-1643-8. PMID: 29796844
Linehan WM
J Urol 1988 Feb;139(2):340-1. doi: 10.1016/s0022-5347(17)42405-0. PMID: 3339737

Therapy

Rappold PM, Silagy AW, Kotecha RR, Hakimi AA
J Surg Oncol 2021 Mar;123(3):739-750. doi: 10.1002/jso.26339. PMID: 33595892Free PMC Article
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL
Cancer Treat Rev 2020 Jun;86:102017. Epub 2020 Mar 26 doi: 10.1016/j.ctrv.2020.102017. PMID: 32335505
Gross-Goupil M, Bernhard JC, Ravaud A
Expert Opin Investig Drugs 2012 Nov;21(11):1727-32. Epub 2012 Aug 9 doi: 10.1517/13543784.2012.713935. PMID: 22876762
Houghton PJ
Clin Cancer Res 2010 Mar 1;16(5):1368-72. Epub 2010 Feb 23 doi: 10.1158/1078-0432.CCR-09-1314. PMID: 20179227Free PMC Article
Limvorasak S, Posadas EM
Expert Opin Pharmacother 2009 Dec;10(18):3091-102. doi: 10.1517/14656560903436493. PMID: 19954277

Prognosis

Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Rampulla V, Barni S, Cabiddu M, Bossi A, Ghidini A, Zaniboni A
JAMA Netw Open 2021 Mar 1;4(3):e213520. doi: 10.1001/jamanetworkopen.2021.3520. PMID: 33779745Free PMC Article
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators
Lancet Oncol 2016 Jul;17(7):917-927. Epub 2016 Jun 5 doi: 10.1016/S1470-2045(16)30107-3. PMID: 27279544
Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME
J Urol 2016 Oct;196(4):989-99. Epub 2016 May 6 doi: 10.1016/j.juro.2016.04.081. PMID: 27157369Free PMC Article
Lane BR, Novick AC
BJU Int 2007 May;99(5 Pt B):1245-50. doi: 10.1111/j.1464-410X.2007.06831.x. PMID: 17441918
Yagoda A, Abi-Rached B, Petrylak D
Semin Oncol 1995 Feb;22(1):42-60. PMID: 7855619

Clinical prediction guides

Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, Pietrantonio F, Ferrere G, Fahrner JE, Le Chatellier E, Pons N, Galleron N, Roume H, Duong CPM, Mondragón L, Iribarren K, Bonvalet M, Terrisse S, Rauber C, Goubet AG, Daillère R, Lemaitre F, Reni A, Casu B, Alou MT, Alves Costa Silva C, Raoult D, Fizazi K, Escudier B, Kroemer G, Albiges L, Zitvogel L
Eur Urol 2020 Aug;78(2):195-206. Epub 2020 May 4 doi: 10.1016/j.eururo.2020.04.044. PMID: 32376136
Leibovich BC, Lohse CM, Cheville JC, Zaid HB, Boorjian SA, Frank I, Thompson RH, Parker WP
Eur Urol 2018 May;73(5):772-780. Epub 2018 Feb 3 doi: 10.1016/j.eururo.2018.01.005. PMID: 29398265
Georgiades C, Rodriguez R
Tech Vasc Interv Radiol 2013 Dec;16(4):230-8. doi: 10.1053/j.tvir.2013.08.006. PMID: 24238378
Sandim V, Pereira DA, Ornellas AA, Alves G
Urol Int 2010;84(4):373-7. Epub 2010 Mar 12 doi: 10.1159/000296283. PMID: 20224258
McDermott DF, Atkins MB
Semin Oncol 2006 Oct;33(5):583-7. doi: 10.1053/j.seminoncol.2006.06.004. PMID: 17045087

Recent systematic reviews

Siva S, Louie AV, Kotecha R, Barber MN, Ali M, Zhang Z, Guckenberger M, Kim MS, Scorsetti M, Tree AC, Slotman BJ, Sahgal A, Lo SS
Lancet Oncol 2024 Jan;25(1):e18-e28. doi: 10.1016/S1470-2045(23)00513-2. PMID: 38181809
Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N
Cochrane Database Syst Rev 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2. PMID: 37146227Free PMC Article
Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP
Eur Urol 2022 Nov;82(5):529-542. Epub 2022 Sep 10 doi: 10.1016/j.eururo.2022.08.019. PMID: 36100483
Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA
J Clin Oncol 2022 Sep 1;40(25):2957-2995. Epub 2022 Jun 21 doi: 10.1200/JCO.22.00868. PMID: 35728020
Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME
J Urol 2016 Oct;196(4):989-99. Epub 2016 May 6 doi: 10.1016/j.juro.2016.04.081. PMID: 27157369Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...